|Articles|October 12, 2012

Trading Away the Medicines of Tomorrow

Author(s)Mike Hennessy

One of the major issues being negotiated right now the amount of protection for the intellectual property of pharmaceutical and biotech companies. And failure to protect the intellectual property rights will actually hurt patients more than the companies.

Click here to view this article.

Newsletter

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!

Related Content

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?
In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

View more
Burst CME: Targeted Therapy for Optimal Psoriasis Management
Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

View more
Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management
Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

View more
Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update
Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

View more